Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Helix BioMedix, a developer of bioactive peptides, has entered into a four-year agreement with RubyDerm Bio, according to which RubyDerm will, on an exclusive basis, distribute certain company's branded skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in China, Japan and South Korea.
Subscribe to our email newsletter
The four-year agreement includes some minimum purchases and may be extended through mutual consent.
Stephen Beatty, president and CEO of Helix BioMedix, said: “RubyDerm Bio gives the Company access to three of the major Asian aesthetic and dermatology markets. We are delighted to expand our distribution though this partnership.”
Jerry Jung, president and CEO of RubyDerm Bio, said, “Helix BioMedix has a proven peptide technology base for effective skin care backed by impressive science. We are happy to bring the Cerakine™ brand of skin health products to the South Korean, Chinese and Japanese aesthetic medical markets.”
RubyDerm Bio and its affiliate Mecca Life Sciences encompass four medical clinics, a clinical trials lab, and two trading and marketing companies that specialize in the aesthetic and dermatology market place.
Helix BioMedix’s core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, which are leveraged using its relationships with peptide manufacturers and contract research organizations.